A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration, or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft tissues.

A method is used for preparing a product for use in repairing a lesion or defect at a tissue site in a human or animal patient body. The method includes obtaining tissue from a donor human or animal body and freezing the obtained tissue. The method further includes pulverizing the frozen tissue and suspending the pulverized tissue in a fluid. The method further includes homogenizing the tissue suspension and precipitating tissue particles from the homogenized tissue suspension. The method further includes re-suspending the precipitated tissue particles and lyophilizing the tissue re-suspension to provide the product to be used in repairing the lesion or defect.

The present invention provides customized hybrid bone-implant grafts and a method of manufacture thereof.

The present invention relates to a method for using a lyophilization hyaline cartilage powder to produce a composition for regenerating cartilage, and a composition for regenerating cartilage produced by using the method, the method comprising: A) a step for preparing hyaline cartilage; B) a step for freeze-drying and crushing the hyaline cartilage, and producing a lyophilization hyaline cartilage powder; C) a step for producing an adipose tissue extract from autologous adipose tissue; and D) a step for producing a composition which is for regenerating cartilage and including the lyophilization hyaline cartilage powder and the adipose tissue extract.

A system for the therapeutic treatment of joints comprising a composite material comprising a biodegradable polymer matrix and a plurality of piezoelectric particles adapted to generate local electric charges in response to an external stimulation made by means of ultrasound, said plurality of piezoelectric particles being dispersed in the matrix. The composite material also comprises a plurality of stamina cells dispersed in the biodegradable polymer matrix and a plurality of carbon-based particles. The system also comprises a releasing device, arranged to deposit the composite material in a joint cavity at predetermined areas of the cartilage, and a stimulator device arranged to emit ultrasound at a predetermined frequency, a predetermined intensity and for a predetermined time of application, in such a way that, when the device is located near a joint wherein the composite material has been deposited, said ultrasound stimulate the plurality of piezoelectric particles.

Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.

The present inventors have clarified that activin has an activity of promoting the proliferation of MSCs and an activity of promoting the regeneration of meniscus or cartilaginous tissue without affecting differentiation multipotency. Further, the present inventors have also found that the use of activin makes it possible to treat and prevent meniscus damage or cartilage disorders, including suppression of degenerative degeneration of cartilage and pain.

The present invention relates to a tissue fusion composition having tissue adhesion and differentiation characteristics, and a preparation method therefor. In the present invention, a tissue fusion composition in the form of a gel or sheet is prepared using stem cells and stem cell-derived extracellular matrix, and it has been confirmed that the composition adheres and binds superbly to biological tissues and can be differentiated into cartilage, bone, cornea, growth plate, and the like, and thus the composition can be used as an adhesive and a differentiation agent in regenerative therapy of damaged tissues or organs, therefore being ultimately and effectively usable as an agent for tissue fusion.

The present application relates to a method of inducing differentiation of stem cells into chondrocytes using an oligopeptide, and a pharmaceutical composition for treating cartilage injury disease containing differentiated chondrocytes obtained by the method.

The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.